Every 8-K that Flora Growth Corp. (FLGC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FLGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLGC filings page.
ZeroStack Corp. reported that its independent directors approved new performance-based stock option grants for three senior leaders. The company granted 500,000 options to CEO Daniel Reis-Faria, 250,000 to CFO Dany Vaiman, and 500,000 to Executive Chairman Michael Heinrich.
The options have a $5.10 exercise price, a 10-year term, and are unexercisable until seven days after closing the Share Exchange Agreement involving Texas Blocker Corp. They are also subject to forfeiture unless shareholders approve them at the annual and special meeting expected on or about July 13, 2026. Vesting occurs in five 20% tranches when the share price reaches VWAP thresholds from $7.65 up to $17.85 on any trading day.
ZeroStack Corp. entered into a series of agreements tied to its Zero Gravity (0G) token holdings and a planned share exchange. Texas Blocker Corp., formed by ZeroStack’s CEO and CFO, received 142,232,948 0G Tokens from investors in return for 9,104,614 Texas Blocker common shares, valued at US$0.7549 per Token and US$11.7931 per Blocker Share.
ZeroStack then signed a Share Exchange Agreement to issue 9,104,614 ZeroStack common shares and/or pre-funded warrants in exchange for all outstanding Texas Blocker shares, after required shareholder approvals. On closing, Texas Blocker will become a wholly owned subsidiary and ZeroStack expects to be treated as a U.S. domestic corporation for federal tax purposes under Section 7874(b).
Separately, ZeroStack agreed to settle a prior token-denominated convertible note by delivering 50,000,000 Tokens to Zero Gravity Labs Inc., fully satisfying principal and interest and providing mutual releases. The ZeroStack securities are being issued in an exempt, unregistered private offering framework.
ZeroStack Corp., formerly Flora Growth Corp., has officially changed its corporate name and Nasdaq ticker. Effective January 29, 2026, the company’s name changed from “Flora Growth Corp.” to “ZeroStack Corp.” following previously approved Articles of Amendment under Ontario corporate law.
On the same date, the company’s common shares stopped trading on the Nasdaq Capital Market under the ticker symbol “FLGC” and began trading under the new symbol “ZSTK”. The common shares also received a new CUSIP number, 98956L101 (ISIN: CA98956L1013). Existing share certificates remain valid and do not need to be exchanged.
Flora Growth Corp. reported board and committee changes. On January 6, 2026, the board unanimously appointed Larry Zeifman as a director, as a member of the audit, compensation, and nominating and corporate governance committees, and as Chair of the Audit Committee. The board also named Manfred Leventhal as Chair of the nominating and corporate governance committee.
The board determined that Mr. Zeifman is an independent director who meets Nasdaq and SEC standards for audit and compensation committee service. His appointment fills vacancies created by the passing of director Harold Wolkin on August 25, 2025. The company states there are no special arrangements, family relationships, or related-party transactions tied to Mr. Zeifman’s appointment, and no material compensation plan or award has been granted in connection with his joining the board.
Flora Growth Corp. filed an 8-K reporting a material event and included standard forward-looking statements and risk disclosures. The filing lists potential risks that could materially affect results, including possible impairment charges if the market price of 0G declines below book value, share price volatility from future issuances, uncertainty from changing interest rates, the company’s ability to achieve and maintain profitability, regulatory and compliance complexities, potential changes in accounting for its 0G holdings, general economic conditions, growth management challenges, and access to capital. The statements are dated and the company disclaims any obligation to update forward-looking statements except as required by law.
Flora Growth Corp. disclosed that it has filed a new prospectus supplement for its existing Form S-3 shelf registration to support an updated "at the market" common share sales program with Revere Securities LLC. Under this new ATM prospectus supplement, the company may, at its discretion, sell up to $3,450,000 of common shares over time into the market. These sales can be made from time to time, providing flexible access to equity capital.
As part of this update, Flora Growth terminated the prior ATM prospectus supplement dated September 23, 2025. Under that earlier supplement, the company sold common shares with an aggregate value of $129,482 before ending that specific offering.
Flora Growth Corp. entered into an at-the-market (ATM) sales agreement with Revere Securities LLC to sell its common shares from time to time through Revere as sales agent. Sales will be made under one or more Form S-3 registration statements using ATM methods allowed under securities laws and Nasdaq rules, and either party can suspend the offering with proper notice. Revere will receive a cash commission equal to 3.00% of the first $150 million in aggregate gross proceeds, 2.00% of the next $350 million, and 1.25% of any amount above $500 million from share sales. Flora is not obligated to sell any shares and currently plans to use any net proceeds for general corporate purposes.
Flora Growth Corp. disclosed proposed token and securities financings including a Token Private Placement of 8,546,955 pre-funded warrants at US$25.1899 each, each exercisable for one common share at US$0.0001 upon shareholder approval, with token consideration valued at US$3.00 each. The company also described convertible notes tied to Solana or Tokens that, subject to shareholder approval, may convert into common shares at a conversion ratio based on a US$33.34 reference price and specified U.S. Dollar value calculations. A Loan Agreement with Zero Gravity Labs to borrow Tokens includes issuance of 1,786,423 warrants exercisable at US$0.01. Several agreements include outside/early termination mechanics and optional in-kind interest capitalization through September 30, 2026.
Flora Growth Corp. reported the passing of director Harold Wolkin, who had served as an independent director on its board and key committees. His death leaves the company temporarily out of compliance with Nasdaq corporate governance rules that require a board majority of independent directors and an audit committee of at least three independent members.
The board now has four members, only two of whom are independent, and the audit committee has two independent members. Flora Growth states it is reviewing options to restore compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) within the applicable cure period.